Switzerland· 69865003
Rybelsus N 4 mg, Tabletten
A semaglutide product containing semaglutidum, registered in Switzerland by Novo Nordisk Pharma AG and dispensed under Swissmedic category B, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Semaglutide is registered in 14 of 19 countries.
Countries holding a registration under ATC A10BJ06 (semaglutide), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 9 of them publish a price we can compare per daily dose
Semaglutide · ATC A10BJ06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of semaglutide costs, country by country.
Normalised to the WHO defined daily dose (10.5 mg), the median price runs from $11.85 in Italy to $430.99 in Switzerland — a ×36 gap.
- Switzerland: $430.99 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Semaglutide · price per daily dose (10.5 mg)
USD · FX 28 Sept 2026
- CH Switzerland$430.99
- IT Italy$11.85
The record
At a glance
Swissmedic (Switzerland)- Active substance
- semaglutidum
- Manufacturer
- Novo Nordisk Pharma AG
- Country
- Switzerland (CH)
- ATC code
- A10BJ06
- ATC class
- Semaglutide
- Defined daily dose
- 10.5 mg, O
- Swissmedic category
- B
- Reimbursed
- Yes
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 1
1 priced- gtin7680698650034Blist 90 StkCHF 307.65
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
301 interactions on record for semaglutide.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Semaglutide · interactions on record
301 records
- 3 severe
- 258 moderate
- 40 minor
Most severe, free to view
- GatifloxacinJ01MA16severe
- SucralfateA02BX02moderate
- ThiethylperazinA04AB03moderate
- TriflupromazinA04AD06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Semaglutide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaRYBELSUSNovo Nordisk A/S, Bagsvaerd
- United StatesOZEMPICNovo Nordisk Pharmaceutical Industries, LP
- SwedenRybelsus 4 mg TablettNovo Nordisk A/S
- IrelandRybelsus 4 mg tabletsNovo Nordisk A/S
- SpainRYBELSUS 4 MG COMPRIMIDOSNovo Nordisk A/S
- FinlandRybelsusNovo Nordisk A/S
- NetherlandsRybelsus 4 mg tablettenNovo Nordisk A.S.
- PolandRybelsusNovo Nordisk A/S
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Kayshild, Ozempic
- Norway · Kayshild, Ozempic
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/802fd506-eb70-4c2a-a005-0522f232b86c GET /v1/drugs/802fd506-eb70-4c2a-a005-0522f232b86c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"unit": null,
"strength": "semaglutidum 4 mg",
"valid_from": "2026-04-01",
"limitations": "[{\"description\":\"Zur Behandlung von Patienten mit einem unzureichend kontrollierten Typ 2 Diabetes mellitus ergänzend zu Diät und Bewegung:<br>\\n- In Monotherapie bei Patienten mit nachgewiesener Kontraindikation oder nachgewiesener Unverträglichkeit für Metformin.<br>\\n<br>\\nZur Behandlung von Patienten mit einem Typ 2 Diabetes mellitus in Kombination mit folgenden Therapieoptionen, wenn durch diese Antidiabetika keine ausreichende Blutzuckerkontrolle erreicht wird:<br>\\n- Als Zweifachkombination mit Metformin oder einem Sulfonylharnstoff<br>\\n- Als Dreifachkombination mit einer Kombination aus Metformin und einem Sulfonylharnstoff<br>\\n- In Kombination mit Basalinsulin mit oder ohne Metformin<br>\\n- In Kombination mit einem SGLT-2-Inhibitor mit oder ohne Metformin<br>\\n<br>\\nMindestens BMI 28. Zusätzliche Medikamente zur Gewichtsreduktion werden nicht vom Krankenversicherer vergütet.<br>\\n<br> \\n\",\"costApproval\":null,\"indication\":\"22071.01\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2026-04-01\"}]",
"galenic_form": "Tabl 4 mg",
"therapeutic_area": null,
"sl_inclusion_date": "2026-04-01",
"self_retention_pct": 10
}See everything about semaglutide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.